| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of 1 Biochemistry, 2 Preventive Medicine, and 3 Anatomic Pathology, School of Medicine; 4 Department of Internal Medicine, Kyungpook National University Hospital; 5 Cancer Research Institute, and 6 Health Promotion Research Center, Kyungpook National University, Daegu, Korea
Requests for reprints: Jae Yong Park, Department of Internal Medicine, School of Medicine, Kyungpook National University, Samduk 2Ga 50, Daegu, 700-412, Korea. Phone: 82-53-420-5536; Fax: 82-53-426-2046. E-mail: jaeyong{at}kyungpook.ac.kr
Angiogenesis is an essential process in the development, growth, and metastasis of malignant tumors including lung cancer. DNA sequence variations in the vascular endothelial growth factor (VEGF) gene may lead to altered VEGF production and/or activity, thereby causing interindividual differences in the susceptibility to lung cancer via their actions on the pathways of tumor angiogenesis. To test this hypothesis, we investigated the potential association between three VEGF polymorphisms (–460T > C, +405C > G, and 936C > T)/haplotypes and the risk of lung cancer in a Korean population. VEGF genotypes were determined in 432 lung cancer patients and 432 healthy controls that were frequency matched for age and sex. VEGF haplotypes were predicted using Bayesian algorithm in the phase program. Compared with the combined +405 CC and CG genotype, the +405 GG genotype found associated with a significantly decreased risk of small cell carcinoma [SCC; adjusted odds ratio (OR), 0.36; 95% confidence interval (95% CI), 0.17-0.78]. The 936 CT genotype and the combined 936 CT and TT genotype were also associated with a significantly decreased risk of SCC compared with the 936 CC genotype (adjusted OR, 0.47; 95% CI, 0.26-0.85 and adjusted OR, 0.44; 95% CI, 0.24-0.80, respectively). Haplotype CGT was associated with a significantly decreased risk of SCC (adjusted OR, 0.39; 95% CI, 0.18-0.87), whereas haplotype TCC conferred a significantly increased risk of SCC (adjusted OR, 1.63; 95% CI, 1.14-2.33). None of the VEGF polymorphisms studied significantly influenced the susceptibility to lung cancer except SCC. However, haplotypes TCT and TGT were significantly associated with the risk of overall lung cancer, respectively (adjusted OR, 0.38; 95% CI, 0.25-0.60 and adjusted OR, 3.94; 95% CI, 2.00-7.76, respectively). These effects of haplotypes TCT and TGT on lung cancer risk were observed in three major histologic types of lung cancer. These results suggest that the VEGF gene may be contribute to an inherited predisposition to lung cancer.
This article has been cited by other articles:
|
|
 |
|
  R. Zhai, G. Liu, K. Asomaning, L. Su, M. H. Kulke, R. S. Heist, N. S. Nishioka, T. J. Lynch, J. C. Wain, X. Lin, et al. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk Carcinogenesis, December 1, 2008; 29(12): 2330 - 2334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lurje, W. Zhang, A. M. Schultheis, D. Yang, S. Groshen, A. E. Hendifar, H. Husain, M. A. Gordon, F. Nagashima, H. M. Chang, et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer Ann. Onc., October 1, 2008; 19(10): 1734 - 1741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zhai, G. Liu, W. Zhou, L. Su, R. S. Heist, T. J. Lynch, J. C. Wain, K. Asomaning, X. Lin, and D. C. Christiani Vascular Endothelial Growth Factor Genotypes, Haplotypes, Gender, and the Risk of Non-Small Cell Lung Cancer Clin. Cancer Res., January 15, 2008; 14(2): 612 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Kim, Y. S. Chae, S. K. Sohn, Y. Y. Cho, J. H. Moon, J. Y. Park, S. W. Jeon, I. T. Lee, G. S. Choi, and S.-H. Jun Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer Clin. Cancer Res., January 1, 2008; 14(1): 62 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kim, S. Sohn, Y. Chae, Y. Cho, H-I Bae, G Yan, J. Park, M-H Lee, H. Chung, and W Yu Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer Ann. Onc., June 1, 2007; 18(6): 1030 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Eroglu, S Gulec, C Kurtman, R Cam, and N Akar Vascular endothelial growth factor 936 C/T polymorphism in cancer patients Ann. Onc., September 1, 2006; 17(9): 1467 - 1468. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y. Park, J. M. Park, J. S. Jang, J. E. Choi, K. M. Kim, S. I. Cha, C. H. Kim, Y. M. Kang, W. K. Lee, S. Kam, et al. Caspase 9 promoter polymorphisms and risk of primary lung cancer Hum. Mol. Genet., June 15, 2006; 15(12): 1963 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Y. Jung, J. E. Choi, J. M. Park, M. H. Chae, H.-G. Kang, K. M. Kim, S. J. Lee, W. K. Lee, S. Kam, S. I. Cha, et al. Polymorphisms in the hMSH2 Gene and the Risk of Primary Lung Cancer. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 762 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Jackson, I. Lea, A. Rashid, S. D. Peddada, and J. K. Dunnick Genetic Alterations in Cancer Knowledge System: Analysis of Gene Mutations in Mouse and Human Liver and Lung Tumors Toxicol. Sci., April 1, 2006; 90(2): 400 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Sohn, S. Y. Lee, S. J. Lee, E. J. Kim, S. I. Cha, C. H. Kim, J.-T. Lee, T. H. Jung, and J. Y. Park MDR1 Polymorphisms Predict the Response to Etoposide-Cisplatin Combination Chemotherapy in Small Cell Lung Cancer Jpn. J. Clin. Oncol., March 1, 2006; 36(3): 137 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-S. Jang, S. J. Lee, J. E. Choi, S. I. Cha, E. B. Lee, T. I. Park, C. H. Kim, W. K. Lee, S. Kam, J.-Y. Choi, et al. Methyl-CpG Binding Domain 1 Gene Polymorphisms and Risk of Primary Lung Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2474 - 2480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Park, G. Y. Lee, J. E. Choi, H. G. Kang, J. S. Jang, S. I. Cha, E. B. Lee, S. G. Kim, C. H. Kim, W. K. Lee, et al. No Association between Polymorphisms in the Histone Deacetylase Genes and the Risk of Lung Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1841 - 1843. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
